Similar articles

• Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity.

  Vesikari T, Ruuska T, Green KY, Flores J, Kapikian AZ. Vesikari T, et al. Pediatr Infect Dis J. 1992 Jul;11(7):535-42. doi: 10.1097/00006454-199207000-00006. Pediatr Infect Dis J. 1992. PMID: 1326741 Clinical Trial.
• Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a "Jennerian" approach to vaccination.

  Kapikian AZ, Flores J, Hoshino Y, Glass RI, Midthun K, Gorziglia M, Chanock RM. Kapikian AZ, et al. J Infect Dis. 1986 May;153(5):815-22. doi: 10.1093/infdis/153.5.815. J Infect Dis. 1986. PMID: 3009632 Review. No abstract available.
• [Anti-rotavirus vaccinations].

  Schmitz J. Schmitz J. Arch Pediatr. 1999 Sep;6(9):979-84. doi: 10.1016/s0929-693x(99)80593-4. Arch Pediatr. 1999. PMID: 10519034 Review. French.
• Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group.

  Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA. Bernstein DI, et al. JAMA. 1995 Apr 19;273(15):1191-6. JAMA. 1995. PMID: 7707626 Clinical Trial.
• Virological and serological aspects of immune resistance to rotavirus gastroenteritis.

  Chiba S, Nakata S, Ukae S, Adachi N. Chiba S, et al. Clin Infect Dis. 1993 Mar;16 Suppl 2:S117-21. doi: 10.1093/clinids/16.supplement_2.s117. Clin Infect Dis. 1993. PMID: 8384012 Review.